<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the Month of September, 2000
Commission File Number 0-30860
Axcan Pharma Inc.
-----------------
(Exact Name of Registrant)
597, boul, Laurier, Mont-Saint-Hilaire (Quebec), Canada
-------------------------------------------------------
J3H 6C4 (Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
[X] [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No
[ ] [ ]
This Form 6-K consist of:
A press release issued by Axcan Pharma Inc. on September 1, 2000 entitled "Axcan
Pharma Added to the TSE 300 Composite Index."
<PAGE> 2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AXCAN PHARMA INC.
Date: September 7, 2000 By: /s/ JEAN VEZINA
-------------------------------------
Name: Jean Vezina
Title: Vice-President, Finance and Chief
Financial Officer
Date: September 7, 2000 Investor Contact:
Axcan Pharma Inc. David W. Mims
597, boul, Laurier Executive Vice President and Chief
Mont-Saint-Hillaire(Quebec) Operating Officer
Canada J3H 6C4 Tel: (205) 991-805
Tel: (405) 467-5138
1(800) 565-3255 Isabelle Adjahi
Fax: (450) 464-9979 Director, Investor Relations
www.axcan.com Tel: (450) 467-5138
FOR IMMEDIATE RELEASE
AXCAN PHARMA ADDED TO THE TSE 300 COMPOSITE INDEX
MONT SAINT-HILAIRE, QUEBEC - Axcan Pharma Inc. ("Axcan") is pleased to announce
that the Company has been added today to the TSE 300 Composite Index.
"This addition to the TSE 300 is a tremendous recognition of Axcan's progress
over the past few years," commented Leon F. Gosselin, President and CEO. "This
places us among Canada's leading companies and will definitely increase investor
awareness," he added.
The TSE 300 Composite Index was created in 1977 by the Toronto Stock Exchange
and is maintained by Standard & Poor's. Comprised of 300 of Canada's larger
public companies traded on the Toronto Stock Exchange, the TSE 300 is widely
regarded as a barometer of Canadian equity markets. Inclusion to the TSE 300 is
made only after review by Standard & Poor's and in accordance with strict
criteria.
<PAGE> 3
Axcan is a leading North American pharmaceutical company in the field of
gastroenterology. Axcan is the only Canadian pharmaceutical company with its own
US sales and marketing organization and its common shares are listed on the
Toronto Stock Exchange under the symbol "AXP" and on the NASDAQ National Market
under the symbol "AXCA".
This press release contains forward-looking statements, which reflect the
Corporation's current expectation regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the successful and timely completion of clinical studies, the
uncertainties related to the regulatory process and the commercialization of the
drug or vaccine thereafter. Investors should consult the Corporation's ongoing
quarterly filings, annual reports and other filings for additional information
on risks and uncertainties relating to these forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements. The
Corporation disclaims any obligation to update these forward-looking statements.
